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Purpose. To identify the optimal vehicle for fast and efficient cellular
production of the photosensitizer, protoporphyrin IX (PpIX), upon
administration of 5-aminolevulinic acid (ALA).
Methods. ALA in various oil/water o/w emulsions was applied to the
human mammary epithelial cell line (MCF-7) cultured in microplates.
Upon incubation for 1–4 h, the accumulated amount of PpIX was
determined by fluorescence spectroscopy. Variables such as the pH
and concentration of the emulsions, the temperature and duration of
incubation were examined along with the importance of ALA con-
centration and the presence of endocytosis inhibitors.
Results. An increase in the amount of produced PpIX was observed
with an increase in extracellular pH, incubation temperature, and
ALA concentration. A saturable mechanism of PpIX accumulation
was evident, mainly as a result of the uptake mechanism for ALA.
Some of the o/w emulsions increased the amount of intracellular
PpIX, and the results indicated that this was not due to an increased
km of the extracellular ALA to intracellular PpIX conversion, but to
the increased endocytotic uptake in the presence of the emulsions. In
general, the increase in PpIX in the presence of emulsions relative
to the control was more pronounced after 1 h as compared to after
2–4 h.
Conclusions. The formation of PpIX in MCF-7 cells exposed to ALA
is improved by the presence of certain o/w emulsions, which could be
explained by endocytosis.
KEY WORDS: aminolevulinic acid uptake; endocytosis; MCF-7
cells; oil-in-water emulsions; photodynamic diagnosis and therapy;
protoporphyrin IX.
INTRODUCTION
Photodynamic diagnosis and therapy is a noninvasive
technique well suited for light-accessible superficial neoplas-
tic cells (1). A range of studies have shown that topically
applied 5-aminolevulinic acid (ALA)—a heme precursor—in
photodynamic diagnosis and therapy of oncologic (2) and
non-oncologic pathologies (3) is superior to conventional
treatments. Under physiologic conditions, the synthesis of
ALA from glycine and succinyl CoA is inhibited by a negative
feedback mechanism caused by heme, but if exogenous ALA
is introduced, the amount of the metabolite protoporphyrin
IX (PpIX) increases (1,2). PpIX induces apoptosis, is the
main endogenous photosensitizer derived from ALA, and it
tends to accumulate more easily in tumor tissue compared to
normal tissue. The reason for this is not precisely known, but
probably depends on a variety of factors, such as an increased
uptake or increased affinity of ALA caused by the neoplastic
cells, a faster metabolism to PpIX due to slightly higher tem-
peratures in tumor cells as compared to normal cells, or a
decreased transformation of PpIX to heme (1,2).
The main clinical limitations with ALA are its instability
at physiologic pH as well as its hydrophilicity, which result in
relatively low cellular uptake. ALA is relatively stable at
lower pH values (4,5), as dimerization—and further forma-
tion of metabolites—depends on the amount of anionic ALA.
The pKa values of ALA in an aqueous solution are approxi-
mately 4 and 8 (5); thus, at pH values below 4, ALA is quite
stable. Other parameters, which strongly influence ALA sta-
bility, encompass the ALA concentration in a formulation, as
well as the viscosity and storage temperature of the formula-
tion (6). Approaches taken to increase the cellular uptake
have mainly dealt with increasing the passive diffusion of
ALA across the plasma membrane by using more lipophilic
ALA prodrugs (7,8). Especially ALA-methylester was effec-
tive in a range of clinical trials (1). When using ALA-
hexylester, PpIX formation was 2.5–3.5 times higher for up to
24 h of incubation in cell cultures (8). In vivo, the increase
was, however, merely 1.3 (8) and in organ cultures, PpIX
formation was not increased with the hexylester (7). Another
approach is to target ALA to the mitochondria by increasing
the affinity for the mitochondrial membrane, which might be
achieved by the use of specific lipids in the formulation (9).
Topical application of ALA in formulations with increased
ALA stability and/or permeability has been investigated us-
ing gels (10) and films (11). Furthermore, encapsulation of
ALA in nanoparticles and application as colloidal lotion was
highly effective, probably due to increased chemical stability
of ALA (12). Water-in-oil and oil-in-water formulations have
been used in clinical studies, all with therapeutic success (13),
which probably is due to increased stability of ALA as well as
improved permeability of ALA across the biological barrier.
However, a more recent study showed that the accumulation
of ALA in a murine subcutaneous adenocarcinoma in vivo
model was higher when applied topically in saline (with or
without DMSO) as compared to a w/o-based cream, vaseline
or liposomes (14). Furthermore, incorporation of ALA into
liposomes did not increase the rate of PpIX synthesis, neither
in tissue explant culture nor in the M2 mammary adenocar-
cinoma cell line (7).
An increased active uptake of ALA could improve its
therapeutic effect. ALA is recognized as a substrate by sev-
eral membrane transporters. For example, PEPT2 translo-
cates 3H-ALA by means of a saturable transport mechanism
(15). The authors of that study concluded that for neutral
compounds, such as ALA, extracellular pH only alters the
maximal transport rate, but not the affinity to the transporter
(15). The PEPT2 transporter seems to be expressed in mam-
mary gland epithelium (16), and RT-PCR screening of rabbit
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mammary gland also showed the presence of mRNA for the
PEPT2 transporter (15). Recently, PEPT1 was found to trans-
port ALA into epithelial cells of the extrahepatic biliary duct
with an apparent affinity constant of 2.1 mM (17). In intesti-
nal Caco-2 cells, mainly the PEPT1 and the basolateral pep-
tide transporter with the km values of 1.6 and 2.4 mM, respec-
tively, translocated ALA (18), and the uptake of ALA was
only slightly inhibited by GABA. On the contrary, in a mu-
rine mammary adenocarcinoma cell line, the uptake of ALA
was mediated by a BETA transporter, as inhibition was seen
with GABA and not with substrates for the PEPT1 and
PEPT2 transporters (19); here, the ALA efflux was diffusion
controlled (20). Also in a human colonic adenocarcinoma cell
line, ALA was found to be a substrate for the BETA trans-
porter (21).
Because an increased uptake of ALA may both reduce
the amount of drug to be applied as well as shorten the time
of incubation before diagnosis or therapy, the objective of the
present study was to optimize uptake and/or metabolism of
ALA in MCF-7 cells, that is, to assess the overall kinetics of
PpIX formation. The MCF-7 cell line is derived from pleural
effusion from a metastatic breast carcinoma. The cells are of
human origin and presumed to conserve some differentiated
mammary epithelial cell function (22), that is, potentially the
PEPT2 transporter. MCF-7 cells have previously been used in
studies with photosensitizers (23). In particular, the effect
which different oil/water (o/w) emulsions have on the amount
of PpIX formed was evaluated. Different endocytosis inhibi-
tors were investigated to assess mechanistic features associ-
ated with the o/w formulations.
MATERIALS AND METHODS
Materials
The MCF-7 cells (no. HTB-22) were from ATCC. Fetal
bovine serum (FBS) was from BioChrom (Berlin, Germany),
whereas Optimem 1, penicillin/streptomycin, trypsin-EDTA,
phosphate-buffered saline free of MgCl2 and CaCl2 (PBS),
RPMI 1640 with L-glutamine but without phenol red (RPMI),
and Hanks balanced salt solution (HBSS) were from Gibco
(Paisley, UK).
96-well Optilux black with transparent polystyrene bot-
tom (Falcon, Becton Dickinson Labware, Franklin Lakes, NJ,
USA) were used for the uptake experiments and transparent
polystyrene 96-well plates (TPP, Trasadingen, Switzerland)
were used for the dehydrogenase activity assays.
5-Aminolevulinic acid HCl (ALA) was synthesized by
Sochinaz (Vionnaz, Switzerland) and kindly provided by
ASAT (Zug, Switzerland). Intralipid 10% (IL10) and Li-
povenös 20% (LV20) were from Fresenius Kabi (Stans, Swit-
zerland). Squalene, glycerol and L--phosphatidyl-L-serin so-
dium salt were from Fluka (Buchs, Switzerland), Synperonic
F68 from ICI (Middlesborough, UK), Lipoid E PC from Li-
poid (Ludwigshafen, Germany), and phosphatidylglycerol
(1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol sodium salt)
from Sygena (Liestal, Switzerland). Ammonium chloride
(NH4Cl), D-mannitol, monensin sodium salt, brefeldin A, cy-
tochalasin D, and Triton X-100 were from Fluka (Buchs,
Switzerland). Protein assay kit [bicinchoninic acid (BCA) so-
lution and 4% CuSO4(H2O)5] and phenazine methosulfate
(PMS) were purchased from Sigma-Aldrich (St. Louis, MO,
USA), and CellTiter 96 AQueous MTS Reagent Powder was
from Promega (Madison, WI, USA).
Preparation of O/W Emulsions
The emulsifiers, glycerol and water were mixed and
stirred magnetically until dissolution, which took a few min-
utes at room temperature for the mixture with Synperonic
F68, and 1 h at 50°C for the mixtures containing the phos-
phatidyl compounds (Table I). The oil phase was then added
and the mixtures emulsified by high-speed mixing at 5000 rpm
for 10 min at 50°C (Polytron, Kinematica, Littau-Lucerne,
Switzerland). Then, the emulsions were homogenized
through 5 passages in a Microfluidizer (M-110T, Microfluid-
ics, Newton, MA, USA). The obtained nanoemulsions (Table
I) were stored at 4°C until further use.
The droplet size, measured by laser light diffraction
(Zetasizer 3, Malvern Instruments, Worchester, UK), was in
the range of 350–400 nm for the commercial emulsions and
for SOPG(0.6), SOPG(0.2) and SOPS(0.2), while it was in the
range of 220–240 nm for SQF68. The zeta potential of the
O-droplets was measured in triplicate by electrophoretic mo-
Table I. Composition of the O/W-Emulsions
Component IL10 LV20 SQF68 SOPG (0.6) SOPG (0.2) SOPS (0.2)
Quantity (%) (w/v) (w/v) (w/w) (w/w) (w/w) (w/w)
Soya oil 10.0 20.0 10.0 10.0 10.0
Squalene 10.0
Synperonic F68 1.2
Egg lecithin 1.2 1.2a 0.6b 1.0b 1.0b
Phosphatidylserine 0.2
Phosphatidylglycerol 0.6 0.2
Glycerine 98% 2.2 2.2 2.2 2.2 2.2
Water 86.6 78.8 86.6 86.6 86.6 86.6
Zeta potential (mV)c −30.3 ± 1.0 −28.2 ± 0.8 −0.3 ± 2.3 −15.3 ± 2.3 −9.6 ± 2.3 −15.5 ± 2.3
a 3-sn-phosphatidylcholin egg lecithin.
b Lipoid E PC.
c Mean ± SD, n  3.
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bility (Zetasizer 3 equipped with electrophoretic cell AZ-55,
Malvern Instruments, Worchester, UK) (Table I). All emul-
sions were isoosmolar and had a pH within the range of 7–8.
Cell Culture
Cultured human mammary gland carcinoma cells, MCF-
7, were rinsed with PBS, trypsinized for 2–3 min, resuspended
in Optimem 1 supplemented with 10% FBS, 90 U/ml penicil-
lin, and 90 g/ml streptomycin. Then, 200 l of a cell suspen-
sion with 10,000 cells/ml were seeded in each well of a 96-well
plate. Passages 188–196 were cultivated at 37°C in a humidi-
fied atmosphere of 5% CO2 until 90–100% confluency (6
days) before use. The medium was exchanged on the day
before the experiment.
Dehydrogenase Activity Assay (MTS/PMS assay)
As an indirect measure of cytotoxicity, decrease in dehy-
drogenase activity was measured. In this test, 180 l of me-
dium was removed from each well and replaced by 200 l of
test solution. The test solutions consisted of 20 l of a 10
mg/ml stock solution of ALA in RPMI or in emulsion mixed
with 180 l RPMI (pH 5.7, 6.6, or 7.4) immediately before
use. For all experiments, the pH of the 10 mg/ml stock solu-
tion was adjusted to 5.5 for stability reasons. The concentra-
tion of ALA was 1 mg/ml and the final pH in the test solutions
corresponded to the pH of the buffer, that is, 5.7, 6.6, or 7.4.
The cells were protected from light by aluminum foil and
incubated at 37°C in a humidified atmosphere of 5% CO2 for
4 h. The test solutions were removed, and the wells rinsed
with 3 × 300 l HBSS of 37°C. Then, 125 l MTS/PMS re-
agent mixture diluted in HBSS (240 g/ml MTS and 2.4 g/ml
PMS) (24) were added, followed by incubation at 37°C under
shaking (50 rpm) for 1 h. The absorbance was read at 492 nm
using a THERMOmax microplate reader (Molecular Devices,
Sunnyvale, CA, USA).
The cytotoxicity of ALA in RPMI was examined for a
concentration range of 1 g/ml to 50 mg/ml (n  8). The o/w
emulsions with or without 1 mg/ml ALA were used at a con-
centration of 10% (v/v) in RPMI (n  8). For endocytosis
inhibition, D-mannitol and NH4Cl were tested in a concentra-
tion range of 10 M to 1 M; monensin in the range of 0.1 M
to 5 mM; brefeldin A in the range of 0.036 to 3.6 M; and
cytochalasin D between 0.011 M and 1.1 mM. These tests
were all done with and without 1 mg/ml ALA (n  4).
In each experiment, RPMI was used as negative control
and 2%(v/v) Triton X-100 in RPMI as positive control. As a
blind reference, the assays were performed without cells.
Uptake of ALA and Metabolism to PpIX
For all cell experiments, ALA was added from freshly
prepared stock solutions or emulsions which contained 10
mg/ml of ALA and had a pH-value adjusted to 5.5 for stabil-
ity reasons. In the test solutions, the ALA preparations were
generally diluted in the appropriate buffer to a concentration
of 1 mg/ml and the emulsion generally to 10% (v/v). The pH
was adjusted to the desired value for the experiment.
Effect of the pH Value of the Incubation Medium
Initially, 180 l of the medium was removed and re-
placed by 180 l of RPMI (pH-adjusted to 5.7, 6.6, or 7.4), or
20 l of the o/w emulsions without ALA was mixed with 160
l of pH-adjusted RPMI and added to the cells. Then, 20 l
of a stock solution of ALA in RPMI was added to each well.
Before each reading, mixing was done for 2 s in the fluore-
scence plate reader (FluoroCount plate reader, Packard In-
strument, Meriden, CT, USA). The settings ( underdot excitation: 400
nm;  emission: 620 nm; PMT: 1100V; gain: 12) were kept for
all readings. The standard curve of PpIX was linear up to 400
nM. The final pH value of the test mixture (ALA stock so-
lution in RPMI) was comparable to the initial value of the
RPMI, that is, 5.7–5.8, 6.6–6.7, and 7.4 for the experiments
referred to as pH 5.7, 6.6, and 7.4, respectively. The cells were
protected from light with aluminum foil and incubated for up
to 4 h. Readings of PpIX fluorescence were taken after 0 and
30 min as well as after 1, 2, 3, and 4 h. After 4 h, the viability
of the cells was examined by rinsing carefully with 3 × 300 l
HBSS of 37°C, and adding MTS/PMS reagent mixture to each
well. The number of repetitions was 8.
Effect of Emulsion Concentration
At pH 5.7 and 7.4, the concentration of LV20 and
SOPS(0.2) in the incubation medium was increased 2 and 3
times, respectively, keeping the total volume in each well con-
stant at 220 l. Further, LV20 and SOPS(0.2) were mixed in
equal volumes of 10 l or 20 l each and tested. The experi-
ment was carried out as described as described in “Effect of
the pH Value of the Incubation Medium,” above.
Effect of Temperature and Duration of Preincubation
The cells were kept in RPMI at either 4°C or 37°C for 30
min or 2 h. The test formulations (20 l), with or without 1.0
mg/ml ALA, were mixed with 200 l of RPMI and applied to
the cells. The cells were then washed with ice-cold HBSS (3 ×
300 l), 220 l RPMI was added, and incubation was contin-
ued at 37°C for 4 h, regardless of whether the cells had pre-
viously been incubated at 4°C or 37°C. As a control, MCF-7
cells were incubated at 37°C for 30 min or 2 h with ALA-free
formulations after which ALA in RPMI (1 mg/ml) was added,
and the fluorescence was then measured over 4 h. Through-
out the experiments, protection from light was maintained,
and the fluorescence was measured every hour. The final pH
of the test mixtures was 7.2-7.5. At the end of the experiment,
the test mixtures were removed, and the MTS/PMS assay for
cell viability was performed.
Effect of ALA Concentration
The formation of PpIX after administration of 0–1.0
mg/ml ALA in RPMI at pH 5.7 and pH 7.4 was evaluated.
Identical ALA concentrations were also applied in the pres-
ence of LV20 and SOPS(0.2). The experiment was carried out
as described in “Effect of the pH Value of the Incubation
Medium,” above.
The protein content per well was determined after lysis
of cells treated with RPMI (n  16). Cell lysis was achieved
with 100 l 0.1% TritonX-100 in HBSS for 4 h, and the
amount of protein was assessed by a BCA assay (25).
Effect of Endocytosis Inhibitors
The endocytosis inhibitor NH4Cl was added to the RPMI
in concentrations of 20 and 50 mM. Monensin was used at a
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concentration of 50 M, cytochalasin D at a concentration of
4.9 M, and brefeldin A at a concentration of 8.9 M. Incu-
bation at 37°C for 30 min with the inhibitors in RPMI was
done before the test formulation and ALA were added. Oth-
erwise, the experiment was carried out described in “Effect of
the pH Value of the Incubation Medium,” above.
Data Analysis
The PpIX standard solution (1 M) in the 96-well plate
was scanned using a CARY Eclipse fluorescence spectropho-
tometer (Varian, Zug, Switzerland). At an excitation wave-
length of 400 nm, an emission maximum of 610 nm was ob-
served.
The data was corrected for background (ALA-free test
mixture applied to cells) and normalized relative to the first
measurement (t  0).
For kinetic fitting, Eq. 1 was used to estimate Vmax
and km:
d(PpIX
dt
=
Vmax × CALA
km + CALA
(1)
ANOVA was used to evaluate differences, which were
considered statistically significant if p < 0.05.
RESULTS
Dehydrogenase Activity
Dehydrogenase activity of MCF-7 cells exposed to up to
5 mg/ml ALA in RPMI at pH 7.4 (97 ± 21%) was not de-
creased relative to the control (100 ± 21%), whereas exposure
to 10 mg/ml ALA was significantly more cytotoxic (57 ± 7%)
(p < 0.001). In general, dehydrogenase activity in the cells was
the same at pH 7.4 and 6.6, but decreased to approximately
60% when the pH of the incubation medium was changed to
5.7. For all the examined pH values, however, none of the
ALA-containing test solutions showed differences from the
RPMI, which had been adjusted to the same pH value, even
when higher emulsion concentrations were used indicating
that a decrease in enzyme activity was only due to changes in
the pH-value and not to the formulation.
The endocytosis inhibitors D-mannitol and NH4Cl were
not cytotoxic at concentrations up to 100 mM in RPMI of pH
7.4 (between 90 ± 7% and 103 ± 11%), and the concomitant
presence of 1 mg/ml ALA exerted no influence (p > 0.05).
Monensin up to 500 M (120 ± 23%) and 50 M cytochalasin
D (93 ± 13%) could also be used without any measurable
toxic effects. Brefeldin A did not decrease the cell viability at
3.6 M (116 ± 22%), but did so at 17.8 M (20 ± 15%)(p <
0.001).
Uptake of ALA and Metabolism to PpIX
Effect of the pH Value of the Incubation Medium
When the pH of the final test formulation applied to the
cells was increased from pH 5.7 to 7.4, the amount of PpIX
formed increased significantly (Fig. 1). Compared to the
RPMI-control, the o/w emulsion enhanced the PpIX forma-
tion during the first hour of incubation. However, this differ-
ence became less important with increasing pH and with
longer exposure time. After 4 h incubation, the amount of
PpIX in the control cells was mostly comparable to that of the
cells exposed to the o/w-emulsions.
Effect of Emulsion Concentration
The amount of PpIX formed upon an increase in the
concentration of LV20 and SOPS(0.2) in RPMI at pH 7.4, in
the presence of 1 mg/ml ALA, is shown in Fig. 2. At a 3 times
higher LV20-concentration, the amount of PpIX observed
after 1 and 4 h appeared to be higher. On the contrary, in-
creasing amounts of SOPS(0.2) emulsion did not result in
more PpIX. In RPMI at pH 5.7, the amount of PpIX was not
increased when the concentration of LV20 and SOPS(0.2)
was increased. Mixing of LV20 and SOPS(0.2) resulted in a
decrease in the amount of PpIX (approximately 44 nM
PpIX), as compared to LV20 alone (52 ± 3 nM PpIX), and to
a decrease as compared to SOPS(0.2) alone (26 ± 6 nM
PpIX).
Effects of Temperature and Duration of Preincubation
ALA metabolism to PpIX was examined over 4 h after
the cells were preincubated with 1 mg/ml ALA in different
formulations for 30 min or 2 h, which was subsequently rinsed
off. When preincubation was conducted at 4°C, no uptake of
ALA occurred as no PpIX formed during the subsequent
incubation for 1 and 4 h in ALA-free RPMI at 37°C. Fig. 3
depicts the result after 2 h preincubation. However, the
amount of PpIX seemed to be independent of the time of
preincubation. Preincubation at 37°C resulted in kinetic pro-
files that were all quite similar suggesting that the uptake of
ALA during the pre-incubation was comparable for the
RPMI and emulsion formulations.
Similarly, when the cells were preincubated for 30 min or
2 h with ALA-free formulations, and the formulations were
Fig. 1. Production of PpIX in MCF-7 cells during incubation at 37°C for 1 h () and 4 h ( ) with 1
mg/ml ALA formulations. The formulations (see Table I) were adjusted to pH values of 5.7, 6.6, and 7.4
immediately before addition to the cells. Mean ± SD (n  8).
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then rinsed off, and the cells finally incubated with ALA in
RPMI, no significant effect of the pre-incubation modality
was observed on the ALA uptake and metabolism over 4 h.
For the other formulations, the same tendency was noted. No
cytotoxicity was observed with any of the treatments.
Effect of ALA Concentration
The saturation profiles for the PpIX-formation upon in-
cubation for 1 h and 4 h with ALA in RPMI of pH 5.7 and 7.4,
with and without LV20 and SOPS(0.2), are depicted in Fig. 4.
The process of PpIX formation seems to be saturated when 1
mg/ml ALA is applied to the cells, regardless of the test for-
mulation used. The estimated km and Vmax values are com-
piled in Table II.
After 1 h of incubation Vmax is approximately 10 times
higher in RPMI of pH 7.4 than in RPMI of pH 5.7. Interest-
ingly, Vmax and km values seemed to be unaffected by pH (7.4
or 5.7) when ALA was applied in LV20 or SOPS(0.2), but
both increased when ALA was applied in RPMI. Further-
more, Vmax was approximately 2–4 times and 20–40 times
higher for the emulsions than for RPMI at pH 7.4 and 5.7,
respectively. Statistical analysis of the data points after 1 h at
ALA concentrations of 0.1, 0.5 and 1 mg/ml revealed a sig-
nificantly higher PpIX formation in RPMI at pH 7.4 than at
pH 5.4 (p < 0.001). Very interestingly, at ALA concentrations
of 0.5 mg/ml (p < 0.01) and 1 mg/ml (p < 0.001), the PpIX
formation was higher with LV20 or SOPS(0.2) than with
RPMI at pH 7.4. For the results obtained after 4 h, the Vmax
in RPMI at pH 7.4 was comparable to RPMI at pH 5.7 and to
Vmax in either of the emulsions. At pH 5.7, however, the PpIX
production seemed to reach a lower maximum when ALA
was applied in emulsion. For both 1 h and 4 h results, the
different formulations did not give substantial differences in
the km values even though there was a tendency toward lower
km values for the LV20 emulsion. However, it should be men-
tioned that with LV20, the fitting parameter is not optimal.
Effect of Endocytosis Inhibitors
The presence of PpIX found in MCF-7 cells exposed to
ALA formulations and different endocytosis inhibitors is pre-
sented in Fig. 5. Some of the inhibitors decreased the amount
of PpIX formed in the control cells (17 ± 2 nM/h) exposed to
RPMI, that is, 50 mM NH4Cl (p < 0.001), monensin (p <
0.001), and brefeldin A (p < 0.05). Cytochalasin D seemed to
increase the intracellular amount of PpIX as compared to
control cells (23 ± 6 nM/h) (p < 0.05) and to cause no change
in the effect of the o/w-emulsions.
Fig. 2. Production of PpIX in MCF-7 cells during incubation at 37°C
for 1 h () and 4 h ( ) with 1 mg/ml ALA in LV20 and SOPS(0.2).
Here, different concentrations of LV20 or SOPS(0.2) emulsions were
used in the medium at pH 7.4, with 10% being the standard concen-
tration used. Mean ± SD (n  8).
Fig. 3. Production of PpIX in MCF-7 cells during incubation at 37°C
for 1 h () and 4 h ( ) with ALA-free RPMI (pH 7.4), after prein-
cubation for 2 h with 1 mg/ml ALA in LV20 or SOPS(0.2) emulsion
or RPMI at 4°C or 37°C (pH 7.4). Mean ± SD (n  8).
Fig. 4. PpIX production in MCF-7 cells after incubation at 37°C for
1 h (A) and for 4 h (B) with variable ALA concentrations in different
emulsions and RPMI at pH 7.4 or 5.7. RPMI, pH 5.7 (), RPMI, pH
7.4 (), SOPS(0.2), pH 7.4 (), LV20, pH 7.4 (). Mean values and
SD are presented (n  8) and profiles fitted according to Eq. 1.
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Therefore, only the effect of 20 mM NH4Cl and 20 and 50
mM D-mannitol was considered for PpIX production after
incubation with the o/w emulsions. The PpIX formation was
significantly decreased when the cells were incubated with
ALA in SOPG(0.6), SOPG(0.2), and SOPS(0.2) in the pres-
ence of 20 mM or 50 mM D-mannitol (p < 0.01), or of 20 mM
NH4Cl (p < 0.05). Conversely, NH4Cl and D-mannitol did not
appear to affect the PpIX formation significantly when ALA
was applied to the cells with less negatively charged emulsion
droplets, that is, IL10, LV20 and SQF68, even though a slight
tendency toward reduced PpIX formation was noticed for
IL10 and SQF68 in the presence of 50 mM D-mannitol.
DISCUSSION
Uptake of ALA and Metabolism to PpIX
Effect of pH, Time, Temperature, and Concentration
The PpIX formation in cells exposed to ALA at pH 5.7
was generally higher when applied in the buffered emulsions
than in the buffer solution (Fig. 1). This could indicate that
the emulsions favored the extracellular stability or intracellu-
lar metabolism of ALA at this pH. However, in previous
studies, o/w emulsions (including IL10 and LV20) did not
increase the stability of ALA significantly as compared to a
buffer solution (4). Furthermore, the 3- to 4-fold increase in
the PpIX formation at pH 7.4 compared to pH 5.7 was similar
regardless of whether ALA was applied in o/w emulsions or
in buffer. This indicates that the effect of pH appears to be
certainly important for metabolism although the importance
for uptake should not be excluded. The optimal pH of 7.4 for
incubation correlates well with the fact that the metabolic
cascade from ALA to PpIX occurs in the mitochondria (9).
The amount of PpIX formed in the MCF-7 cells in-
creased with longer exposure time to ALA. This could be due
to both increased uptake and increased intracellular metabo-
lism. The lack of intracellular PpIX formation at 4°C could
simply be the result of a diminished metabolic activity of the
cells. It has been shown that low temperature hinders PpIX
production, but not the penetration of ALA into mouse and
human skin (26). However, since no PpIX was formed in the
cells incubated at 37°C for up to 4 h following pre-incubation
with ALA for up to 2 h at 4°C, cellular uptake of ALA also
appears to depend on temperature, which supports an uptake
mechanism by transporter(s) or endocytosis. In accordance
with previous findings, the intracellular accumulation of PpIX
upon application of ALA occurs by saturable kinetics (7),
with saturation manifesting in the concentration range of 0–1
mg/ml (Fig. 4). The conversion from extracellular ALA to
intracellular PpIX is probably best described by a two-
compartment model with Michaelis-Menten kinetics (27). It
has previously been shown that the affinity of ALA for the
receptor (km) is not altered by changes in the extracellular
pH, whereas the maximal transport rate (Vmax) is (15). A
comparable observation derives from the present study, when
ALA was applied in buffer. However, when o/w emulsions
were used, Vmax seemed to remain unaffected by a change in
pH. This difference in the maximum amount of PpIX formed
when applying the LV20 or the SOPS(0.2) emulsion for 1 h, as
compared to buffer, could be due to either changes in the
uptake mechanism or effects of emulsion components on the
metabolism in terms of inducing or inhibiting certain enzymes
of the heme synthesis pathway, or else effects of emulsion
components on the rate of distribution to the mitochondria.
The latter two mechanisms require that the cells ingest emul-
sion components, a phenomenon which deserves further in-
vestigations. Because Vmax after 4 h in RPMI at pH 5.7 is
Fig. 5. Inhibition of PpIX production in MCF-7 cells after incubation
at 37°C for 1 h with 1 mg/ml ALA in emulsion or RPMI, pH 7.4.
No inhibitor (), 20 mM NH4Cl ( ), 50 mM mannitol ( ). Mean +
SD (n  8).
Table II. Vmax and km Values for Production of PpIX in MCF-7 Cells after Incubation for 1 h and 4 h in RPMI or Emulsion at pH 5.7
or 7.4a
ALA
formulation
pH of incubation
medium
1 h 4 h
km
(mg/ml)
Vmax
(nM)b
R2 km
(mg/ml)
Vmax
(nM)b
R2
RPMI 5.7 0.10 ± 0.02 1.66 ± 0.09 0.9647 0.12 ± 0.04 173.53 ± 16.54 0.8981
LV20 5.7 0.09 ± 0.06 65.70 ± 11.73 0.5111 0.06 ± 0.04 74.35 ± 13.50 0.5683
SOPS(0.2) 5.7 0.17 ± 0.08 39.32 ± 6.53 0.7102 0.09 ± 0.04 67.97 ± 8.95 0.8056
RPMI 7.4 0.25 ± 0.07 16.80 ± 1.80 0.9478 0.10 ± 0.02 185.92 ± 12.70 0.9285
LV20 7.4 0.07 ± 0.02 63.64 ± 5.53 0.7718 0.05 ± 0.02 176.20 ± 15.52 0.8881
SOPS(0.2) 7.4 0.24 ± 0.09 39.44 ± 5.55 0.8910 0.17 ± 0.02 173.60 ± 6.33 0.9865
a Fitting according to Eq. 1. Mean ± SD (n  8).
b The amount of protein per well was 1.82 ± 0.09 mg/well (n  16).
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comparable to that after 4 h in RPMI at pH 7.4, it seems that
during the first hour of incubation, the uptake of ALA is the
rate-limiting step. The fact that the PpIX formation upon 4-h
exposure to the emulsions is lower at pH 5.7 compared to pH
7.4 suggests that the emulsions limit the long-term accumula-
tion of PpIX at low pH. Interestingly, this difference is not
observed at pH 7.4, suggesting a different mechanism of ac-
tion for the emulsions at different pH values.
In general, the effects of pH, time, temperature and con-
centration observed in this study reflect a saturable uptake of
ALA and future examination of the presence of specific
transporters in the MCF-7 cell line is, therefore, of interest.
Both the PEPT2 and BETA transporters have been suggested
to transport ALA There is strong evidence for the presence of
the PEPT2 transporter in mammary gland epithelium (15).
Contrastingly, the BETA transporter, but not the PEPT2
transporter (16) has been identified in a mammary epithelial
cell line (19,20).
Effect of O/W Emulsion
The accumulation of PpIX in MCF-7 cells was increased
when the amphoteric ALA was formulated in certain o/w-
emulsions—especially LV20 and SOPS(0.2) (Fig. 1). Previ-
ously, an o/w nanoemulsion has been shown to increase the
cellular fluorescence very slightly after uptake of another
photosensitizer, mTHPC (meta-tetra(hydroxypropyl)chlo-
rine), in macrophage-like cells (J774), but to decrease the
uptake of the mTHPC in HT29 adenocarcinoma cell line
(28). DMSO in an o/w-emulsion has been demonstrated to
improve the permeation of ALA across mouse skin in vitro
(29) and in vivo (14) and also with increased PpIX synthesis
(14).
The mechanisms responsible for the enhanced PpIX for-
mation in the presence of emulsions could be explained by the
present results. As ALA is an amphoteric molecule, it prob-
ably interacts strongly through ionic forces with the ampho-
teric lecithin used as emulsifier in most of the tested emul-
sions (Table I). An excess concentration of ALA at the o/w
interface could have promoted the contact between ALA and
the cell surface, resulting in an increased local concentration
of ALA at the cell surface. Such locally increased ALA con-
centration at the epithelial surface could have favored cellular
uptake of ALA, which probably occurred via endocytosis and
not, as previously stated, by an increased affinity for (or ve-
locity of) a transporter. In this context, it may be appropriate
to consider the role of clathrin-coated pits in cellular plasma
membranes. It has been shown that certain endogenous pro-
teins/receptors become clustered in coated pits upon binding
to soluble ligands (30), and that such clustering can result in
an invagination to vesicles/endosomes, which are acidified.
This hypothetic mechanism could explain the present results
with some of the endocytosis inhibitors used, which decreased
the amount of PpIX in the cells. Indeed, hyperosmolarity
induced by mannitol as well as acidification of the cytoplasm
induced by NH4Cl decreased the formation of PpIX in a con-
centration dependent manner (Fig. 5). This coincides with
previous observations that endocytosis mediated by coated
pits is inhibited by hyperosmolarity (by mannitol) and acidi-
fication of the cytoplasm (by NH4Cl) (31), whereas endocy-
tosis via non-coated pits is not inhibited by hyperosmolarity
(32).
The oil droplets of the o/w-emulsions did not interact
with the cell plasma membrane in a harmful way, since none
of the emulsions induced any decrease in dehydrogenase ac-
tivity. Furthermore, no effect on plasma membrane integrity
was noticed, since 30 min pre-incubation with ALA-free test
formulations followed by incubation with ALA formulations
for up to 4 h did not alter the accumulation of PpIX as com-
pared to pre-incubation with buffer (Fig. 3).
The type or charge of the phospholipid in the o/w-
emulsions seemed to be important to the amount of ALA
endocytosed and PpIX formed, as LV20 yielded a higher
Vmax than SOPS(0.2) (Tables I and II). This is also supported
by the data obtained from the inhibitor study (Fig. 5). Here,
the IL10 and LV20 formulations produced higher amounts of
PpIX than SOPG(0.6) and SOPG(0.2) in which up to 50% of
the phosphatidylcholine/lecithin was replaced by the nega-
tively charged phosphatidylglycerol. For the formulations
which was added only 16% phosphatidylglycerol, SOPG(0.2),
or 16% of negatively charged phosphatidylserine, SOPS(0.2),
the difference in the amount of PpIX formed is less evident.
Further support for the beneficial effect of the amphoteric
phosphatidylcholine over the anionic phosphatidyl deriva-
tives is provided by the increased PpIX formation with in-
creasing concentrations of LV20 (10–30%) in the incubation
medium on one side and by the lowered PpIX production
with increasing SOPS(0.2) concentrations on the other side
(Fig. 2). Whether the zeta potential played a significant role
remains uncertain. The negatively charged oil droplets in
LV20 should be repelled by the plasma membrane more
strongly, at least in theory, than the less negatively charged oil
droplets of SOPS(0.2) (Table 1). Furthermore, the fact that
the amount of PpIX formed at pH 7.4 in the presence of ALA
in the SQF68 formulation does not differ significantly from
the SOPG and SOPS emulsions suggests that the type of oil,
the droplet size and zeta potential play a minor role.
In conclusion, the present data show that the formation
of PpIX in MCF-7 cells exposed to ALA depends on pH as
well as time, temperature and concentration—both when
ALA is applied in buffer and in o/w-formulations. By intro-
ducing ALA in an o/w-emulsion, it may be possible to use
lower concentrations of ALA and shorten periods of incuba-
tion for accumulation of PpIX in epithelial cells in order to
diagnose and treat superficial neoplastic cells. This could not
only reduce the risk of side effects by the treatment, but also
save time. The present results raise questions regarding the
exact mechanisms involved and require further studies with
organ cultures of normal cells and tumor cells or in vivo stud-
ies to ascertain tumor selectivity.
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